Dishman Carbogen Amcis Limited (NSE:DCAL)
196.10
+0.34 (0.17%)
Feb 18, 2026, 10:40 AM IST
Dishman Carbogen Amcis Revenue
Dishman Carbogen Amcis had revenue of 7.20B INR in the quarter ending December 31, 2025, with 5.49% growth. This brings the company's revenue in the last twelve months to 27.97B, up 5.55% year-over-year. In the fiscal year ending March 31, 2025, Dishman Carbogen Amcis had annual revenue of 27.12B with 3.66% growth.
Revenue (ttm)
27.97B
Revenue Growth
+5.55%
P/S Ratio
1.10
Revenue / Employee
25.29M
Employees
1,106
Market Cap
30.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 27.12B | 957.30M | 3.66% |
| Mar 31, 2024 | 26.16B | 2.03B | 8.41% |
| Mar 31, 2023 | 24.13B | 2.72B | 12.72% |
| Mar 31, 2022 | 21.41B | 2.29B | 11.96% |
| Mar 31, 2021 | 19.12B | -1.32B | -6.44% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biocon | 168.27B |
| Anthem Biosciences | 20.02B |
| OneSource Specialty Pharma | 14.19B |
| Blue Jet Healthcare | 11.79B |
| Concord Biotech | 11.59B |
| Supriya Lifescience | 7.35B |
| Panacea Biotec | 6.06B |
| Zota Health Care | 4.73B |
Dishman Carbogen Amcis News
- 6 days ago - Q3 2026 Dishman Carbogen Amcis Ltd Earnings Call Transcript - GuruFocus
- 3 months ago - Q2 2026 Dishman Carbogen Amcis Ltd Earnings Call Transcript - GuruFocus
- 8 months ago - Dishman Carbogen clears US FDA inspection at Naroda facility with no observations - Business Upturn
- 9 months ago - Dishman Carbogen shares in focus after Swiss subsidiary signs CHF 25 million co-investment agreement - Business Upturn
- 9 months ago - Dishman Carbogen Amcis shares surge over 11% as company swings to profit in Q4, EBITDA margin doubles - Business Upturn
- 11 months ago - Dishman Carbogen shares surge 5% after arm gets drug manufacturing licence In China - Business Upturn
- 11 months ago - Dishman Carbogen Amcis subsidiary receives drug manufacturing license in China - Business Upturn
- 1 year ago - Dishman Carbogen Amcis shares jump nearly 2% after board approves Rs 50 crore debenture issuance - Business Upturn